Quest Diagnostics is a leading provider of diagnostic testing, information and services. It touches over 150 million patient lives each year through comprehensive and specialized testing services. The company has a history of strong growth and aims to be the undisputed world leader in diagnostic testing, information and services through a strategy focused on superior patient experience, medical innovation, and expanding its geographic reach. Quest provides guidance for continued revenue and earnings growth in 2009.
Joseph Dal Molin: Implementing VistA internationally: Myth-busting lessons fr...Nuffield Trust
In this slideshow Joseph Dal Molin, President of the E-cology Corporation and Chairman of WorldVistA, outlines Jordan’s health system and its approach to implementing VistA.
Joseph Dal Molin presented at the Nuffield Trust seminar: Sharing international experience: Is implementing the VA's electronic health record system an option for the NHS? in July 2012.
Joseph Dal Molin: Implementing VistA internationally: Myth-busting lessons fr...Nuffield Trust
In this slideshow Joseph Dal Molin, President of the E-cology Corporation and Chairman of WorldVistA, outlines Jordan’s health system and its approach to implementing VistA.
Joseph Dal Molin presented at the Nuffield Trust seminar: Sharing international experience: Is implementing the VA's electronic health record system an option for the NHS? in July 2012.
Service Improvement for Radiologists
a signposting document summarising service improvement methodology and benefits
Success factors - general
Success factors - computerised tomography
Service Improvement for Radiologists
a signposting document summarising service improvement methodology and benefits
Success factors - general
Success factors - computerised tomography
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
NeoGenomics overview presetnation ontains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after
NeoGenomics Company Overview highlights. It includes investment highlights, Consistent historical growth charts, accelerating cash flow & earnings, management team, testing services, customer targets, formula for success, industry dynamics, U.S. cancer market size, cancer testing market characteristics, key growth drivers...
NeoGenomics Forward-looking statements, Investment Highlights, Consistent Historical Growth, Accelerating Cash FLow & Earnings, Management Team, Cancer Testing Services, Customer Targets, NeoGenomics Formula for Success, Industry Dynamics, US Cancer Testing Market Size, Cancer Testing Market Characteristics, Key Growth Drivers Over the Next 3 Years...
This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events.
In this NeoGenomics Laboratory Company Overview Presentation 02/19/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
Similar to quest diagnostics 8171932C-60AA-469C-929A-995B7737DF39_BarclaysPresentation3.10.09 (20)
2. Elemental Economics - Mineral demand.pdfNeal Brewster
After this second you should be able to: Explain the main determinants of demand for any mineral product, and their relative importance; recognise and explain how demand for any product is likely to change with economic activity; recognise and explain the roles of technology and relative prices in influencing demand; be able to explain the differences between the rates of growth of demand for different products.
STREETONOMICS: Exploring the Uncharted Territories of Informal Markets throug...sameer shah
Delve into the world of STREETONOMICS, where a team of 7 enthusiasts embarks on a journey to understand unorganized markets. By engaging with a coffee street vendor and crafting questionnaires, this project uncovers valuable insights into consumer behavior and market dynamics in informal settings."
Turin Startup Ecosystem 2024 - Ricerca sulle Startup e il Sistema dell'Innov...Quotidiano Piemontese
Turin Startup Ecosystem 2024
Una ricerca de il Club degli Investitori, in collaborazione con ToTeM Torino Tech Map e con il supporto della ESCP Business School e di Growth Capital
how to sell pi coins in Hungary (simple guide)DOT TECH
If you are interested in selling your pi coins, i have a verified pi merchant, who buys pi coins and resell them to exchanges looking forward to hold till mainnet launch.
Because the core team has announced that pi network will not be doing any pre-sale. The only way exchanges like huobi, bitmart and hotbit can get pi is by buying from miners.
Now a merchant stands in between these exchanges and the miners. As a link to make transactions smooth. Because right now in the enclosed mainnet you can't sell pi coins your self. You need the help of a merchant,
i will leave the what'sapp contact of my personal pi merchant below. 👇
+12349014282
The secret way to sell pi coins effortlessly.DOT TECH
Well as we all know pi isn't launched yet. But you can still sell your pi coins effortlessly because some whales in China are interested in holding massive pi coins. And they are willing to pay good money for it. If you are interested in selling I will leave a contact for you. Just what'sapp this number below. I sold about 3000 pi coins to him and he paid me immediately.
+12349014282
where can I find a legit pi merchant onlineDOT TECH
Yes. This is very easy what you need is a recommendation from someone who has successfully traded pi coins before with a merchant.
Who is a pi merchant?
A pi merchant is someone who buys pi network coins and resell them to Investors looking forward to hold thousands of pi coins before the open mainnet.
I will leave the what'sapp contact of my personal pi merchant to trade with
+12349014282
Seminar: Gender Board Diversity through Ownership NetworksGRAPE
Seminar on gender diversity spillovers through ownership networks at FAME|GRAPE. Presenting novel research. Studies in economics and management using econometrics methods.
2. Who is Quest Diagnostics?
•Leader in Providing Healthcare Insights and Solutions
• Comprehensive Diagnostic Testing
• Routine ——» Esoteric
Diagnose
•
Monitor
•
Predict
•
Prevent
•
–Advanced Information Technology Solutions
• Improve Care and Efficiency
–Facilitate Introduction of New Therapeutics
• Clinical Trials Testing
–Innovative Diagnostic Products
• Enable Care Closer to the Patient
–Risk Assessment Solutions to Life Insurance Industry
Touching Patients 150 Million Times Each Year
Patients | Growth | People
3. History of Strong Growth
20%
Revenue 1999-2008
10-year CAGR 20%
27%
EPS* 1999-2008
10-year CAGR 27%
$ in billions except EPS
Patients | Growth | People
*EPS is from continuing operations
4. Favorable Industry Trends
Essential Healthcare Service
• Growing and Aging Population
• Scientific & Medical Innovations
• Personal Interest in Health
• Convergence of Information
Influences >70% of Healthcare Decisions
Patients | Growth | People
5. Moving to Higher Growth,
Higher Margin Testing Segments
2000 Revenue 2008 Revenue
Total Revenue: $3.4 Billion Total Revenue: $7.2 Billion
Patients | Growth | People
7. Our Longer Term Goals
•Undisputed World Leader in Diagnostic Testing,
Information and Services
•Profitably Grow > Industry Rate
•Expand Operating Income to 20% of Revenues
•Expand International Operations to ~10% of Revenues
Patients | Growth | People
8. Strategy to Drive Profitable Growth
Leverage Capabilities To Create Differentiation
Deliver Superior Patient Experience
Continuously Drive Six Sigma Quality
Lead in Medical Innovation
Leverage Unparalleled Assets & Capabilities
Expand Diagnostic Scope
Expand Geographic Reach
Sustainable Competitive Advantage Patients | Growth | People
9. Delivering Superior Patient Experience
Patient Gold Standards
Prompt, caring, courteous service
PSC Appointment Scheduling
First laboratory with PSC appointment scheduling
Reduces patient wait time; improves convenience
Google Health Collaboration
Facilitate patient-physician communications
Secure electronic access to lab results
Patients | Growth | People
10. Leading Medical Innovator
Multiple Channels to Access New Technology
Internal Development – Nichols Institute
Joint Development Relationships
Licensing/Distribution Relationships
Focused on Addressing Areas of Significant Patient Need
Cancer, Cardiovascular Conditions, Infectious Disease
Less invasive; less painful; more convenient for patients
Leading Experts for Medical Consultation
900 MDs & PhDs
Culture of Collaborative Innovation
Academic relationships
Investment in innovative firms and technologies
Partnerships with pharmaceutical companies
Patients | Growth | People
11. Continual Stream of
Diagnostic Testing Advances
Cancer Transplantation/Coagulation
LeumetaTM HLA FDA-registered lab
HE-4 Coag consultations
H/I Breast Recurrence New Technologies/New Applications
Cancer of Unknown Primary
XSenseTM (Fragile X)
Septin 9 Colorectal Cancer Test
ClarisureTM (CGH Microarray)
Cardiovascular Disease
LC/MS for Amino Acids
Ion Mobility (Lipid Profile)
LC-MS/MS
Infectious Disease
HepaScoreTM
Chikungunya
Patients | Growth | People
Italics – under development
12. Personalized and Targeted Medicine
is an Emerging Opportunity
Enables More Appropriate Drug Therapy
Rituxan® Rituxan® Sensitivity (CD20)
Herceptin® Her2
Campath® Campath Sensitivity (CD2)
Irinotecan UGT1A1
Erbitux® RAS
Warfarin CYP450 2C9
Carbamazephine HLA - screens out certain Asian patients
Abacavir HLA - predisposition to hypersensitivity
Aspirin Monitor personal resistance levels
Improves Disease Management
Leumeta™ CellSearch
Hepascore™
Improving Patient Care …..Reducing Medical Costs
Patients | Growth | People
13. Unparalleled Assets and Capabilities
Serving 50% of US Hospitals & Physicians
2,300 Patient Service Centers and Laboratories
900 MD’s and PhD’s
8,500 Phlebotomists &
5,000 Paramedical professionals
3,500 Courier Vehicles and 25 Airplanes
- making 90,000 stops each day
>140,000 Physician users of Care360
POC testing in >100 Countries
Testing ~1,000,000 Patients a Day through our Labs and POC Devices
Patients | Growth | People
14. Expanding Diagnostic Scope
Near Patient Testing
Opportunity to Improve Patient Care
Attractive benefits for hospitals,
physician offices, rural and
international markets
Enables more timely and
effective decisions
Expanding product menu
Platform technology
Results integrated into Care360
Reducing Medical Costs
Patients | Growth | People
15. Expanding Geographic Reach
Broadening Our Geographical Coverage
Clear leadership in U.S….with room to grow
Leverage existing labs in Puerto Rico, Mexico, and UK
Providing cervical cancer screening for Ireland NHS
Increase foreign testing sent to Nichols Institute
Entered India – serving multiple markets
Increasing Market Opportunity
Patients | Growth | People
16. On Track to Reduce Costs by $500 Million
Leverage Lean Six Sigma to Improve Efficiency
Streamline Lab Operations
Optimize Logistics Routes
and PSC Resources
Improve Billing and Call
Center Operations
Leverage Purchasing
Capabilities
$300 million savings run rate exiting 2008
Maintain Service Levels & Stimulate Growth
Patients | Growth | People
17. 2008 Results
Strong Growth in Revenue, Earnings and Cash Flow
$7.2 B, ↑ 8.1%
Revenues
16.9%, ↑ 0.6%
Operating Income
↑14%
EPS $3.23,
Cash from Operations $1.1 Billion
Patients | Growth | People
18. 2009 Guidance
Continued Revenue & Earnings Growth
↑ ~3%
Revenues
Operating Income % approaching 18%
$3.50 - $3.70, ↑ 8% - 15%
EPS
Cash from Operations * ~$1 billion
CapEx ~$200 million
Strenghening our Leadership Position
*Excludes expected payment of the $316 million reserve
Patients | Growth | People
established for the previously disclosed NID matter
19. Building on Strength
Leader in a vital and growing industry
Uniquely positioned with unparalleled assets & capabilities
History of disciplined growth and successful acquisitions
Strong cash generator, with a strong balance sheet
Proven management team
Focused on Execution
Patients | Growth | People